- Home
- TNGX vs AGNCM Comparison
TNGX vs AGNCM Comparison
Compare TNGX & AGNCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
AGNCM
AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock
Current Price
Company Overview
Basic Information| Metric | TNGX | AGNCM |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TNGX | AGNCM |
|---|---|---|
| Price | $8.65 | $25.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 21.7K |
| Earning Date | 11-04-2025 | 01-26-2026 |
| Dividend Yield | N/A | ★ 8.92% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | $66,501,000.00 | ★ $956,000,000.00 |
| Revenue This Year | $52.80 | $8.02 |
| Revenue Next Year | N/A | $65.46 |
| P/E Ratio | ★ N/A | $16.80 |
| Revenue Growth | ★ 53.29 | N/A |
| 52 Week Low | $1.03 | $23.01 |
| 52 Week High | $11.20 | $25.60 |
Technical Indicators
Market Signals| Indicator | TNGX | AGNCM |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 66.61 |
| Support Level | $8.42 | $24.94 |
| Resistance Level | $8.98 | $25.09 |
| Average True Range (ATR) | 0.55 | 0.14 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 22.47 | 95.77 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About AGNCM AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.